Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution
Kawasaki Disease | Obgyn Key
Frontiers | Thirty Years of Kawasaki Disease: A Single-Center Study at the University Hospital of Lausanne | Pediatrics
Clinical characteristics in Kawasaki disease related to intravenous... | Download Table
Recurrent Kawasaki Disease
Recurrent Kawasaki disease resistant to initial ... - Sudanjp.org
Kawasaki disease - Wikipedia
Kawasaki disease in children: Epidemiology, clinical symptoms and diagnostics of 231 cases in 10 years
The Epidemiology and Clinical Features of Kawasaki Disease in Australia | American Academy of Pediatrics
Kawasaki Disease: Practice Essentials, Background, Pathophysiology
Outcomes of the five patients with Kawasaki disease relapse | Download Scientific Diagram
PDF) Recurrent refractory Kawasaki disease
Recurrent lip swelling as a late presentation of Kawasaki disease: Case report and review of literature – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free
Kawasaki's Disease
Cumulative recurrence rates of Kawasaki disease calculated by different... | Download Scientific Diagram
Frontiers | The Epidemiology and Pathogenesis of Kawasaki Disease | Pediatrics
Kawasaki Disease | American Academy of Pediatrics
Delayed Diagnosis of Kawasaki Disease
Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study | Journal of the American Heart Association
![Full text] Refractory Kawasaki disease: diagnostic and management challenges | PHMT](https://www.dovepress.com/cr_data/article_fulltext/s165000/165935/img/PHMT_A_165935_T0002.jpg "Full text] Refractory Kawasaki disease: diagnostic and management challenges | PHMT")
Full text] Refractory Kawasaki disease: diagnostic and management challenges | PHMT
Kawasaki Disease: Heart Disease During Childhood | Revista Española de Cardiología
2017 AHA Guidelines On Kawasaki Disease – A Link And Excerpts | Tom Wade MD
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
